Key result
Global native T1 mapping was independently associated with major adverse cardiovascular events in patients with hypertrophic cardiomyopathy, providing incremental predictive value over current guidelines.
Why the study?
The role of MRI native T1 mapping and ECV in predicting sudden cardiac death risk and their incremental value over ESC and ACC/AHA guidelines in hypertrophic cardiomyopathy are poorly understood.
Does MRI native T1 mapping and ECV improve prediction of major adverse cardiovascular events in patients with hypertrophic cardiomyopathy?
Cohort (n=304)
No
Does MRI native T1 mapping and ECV improve prediction of major adverse cardiovascular events in patients with hypertrophic cardiomyopathy?
Global native T1 mapping provides incremental value over current ESC and ACC/AHA guidelines in predicting major adverse cardiovascular events in patients with hypertrophic cardiomyopathy, particularly in those classified as low risk.
Answers are grounded in this paper and cite their sources.
Native T1 mapping may refine MACE risk stratification in HCM beyond guidelines; leaves open prospective validation before practice change.
Background: MRI native T1 mapping and extracellular volume fraction (ECV) are quantitative values that could reflect various myocardial tissue characterization. The role of these parameters in predicting the risk of sudden cardiac death (SCD) in hypertrophic cardiomyopathy (HCM) is still poorly understood. Aim: This study aims to investigate the ability of native T1 mapping and ECV values to predict major adverse cardiovascular events (MACE) in HCM, and its incremental values over the 2014 European Society of Cardiology (ESC) and enhanced American College of Cardiology/American Heart Association (ACC/AHA) guidelines. Methods: Between July 2016 and October 2020, HCM patients and healthy individuals with sex and age matched who underwent cardiac MRI were prospectively enrolled. The native T1 and ECV parameters were measured. The SCD risk was evaluated by the 2014 ESC guidelines and enhanced ACC/AHA guidelines. MACE included cardiac death, transplantation, heart failure admission, and implantable cardioverter-defibrillator implantation. Results: A total of 203 HCM patients (54.2 ± 14.9 years) and 101 healthy individuals (53.2 ± 14.7 years) were evaluated. During a median follow-up of 15 months, 25 patients (12.3%) had MACE. In multivariate Cox regression analysis, global native T1 mapping (hazard ratio (HR): 1.446; 95% confidence interval (CI): 1.195–1.749; P < 0.001) and non-sustained ventricular tachycardia (NSVT) (HR: 4.949; 95% CI, 2.033–12.047; P < 0.001) were independently associated with MACE. Ten of 86 patients (11.6%) with low SCD risk assessed by the two guidelines had MACE. In this subgroup of patients, multivariate Cox regression analysis showed that global native T1 mapping was independently associated with MACE (HR: 1.532; 95% CI: 1.221–1.922; P < 0.001). In 85 patients with conflicting results assessed by the two guidelines, end-stage systolic dysfunction was independently associated with MACE (HR: 7.942, 95% CI: 1.322–47.707, P = 0.023). In 32 patients with high SCD risk assessed by the two guidelines, NSVT was independently associated with MACE (HR: 9.779, 95% CI: 1.953–48.964, P = 0.006). Conclusion: The global native T1 mapping could provide incremental values and serve as potential supplements to the current guidelines in the prediction of MACE.
No takes yet. Share an insight, caveat, or question.
Qin et al. (2021) conducted a cohort in Hypertrophic cardiomyopathy (n=304). Global native T1 mapping vs. Standard risk stratification guidelines was evaluated on Major adverse cardiovascular events (MACE) (HR 1.446, 95% CI 1.195-1.749, p=<0.001). Global native T1 mapping was independently associated with major adverse cardiovascular events in patients with hypertrophic cardiomyopathy, providing incremental predictive value over current guidelines.
Synapse has enriched 10 related papers. Consider them for comparative context: